Alisporivir (Debio 025) is a cyclosporine-derived cyclophilin inhibitor with historical clinical development. A 2021 trial does not establish current active status.
SwitzerlandFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
43 matching companiesShowing 1–24 / 43
A publicly traded mRNA drug company with a disclosed platform spanning mRNA design, LNP delivery, and drug substance and drug product manufacturing.
United StatesFull profile →
Develops cancer and infectious disease programs using immunotherapy and mRNA platforms; COMIRNATY is a named product with regulatory validation.
GermanyFull profile →
Develops the LUNAR lipid delivery and STARR self-amplifying mRNA platforms. KOSTAIVE is an approved sa-mRNA COVID-19 vaccine.
United StatesFull profile →
Discloses an integrated mRNA/LNP platform. Its lyophilized shingles mRNA vaccine ABO1108 is in Phase 3 in China. The ABO2203 licensing and option agreement with Novartis announced on 2026-10-02 is not classified as financing.
Mainland ChinaFull profile →
Founded in July 2021, the company focuses on innovative mRNA drugs and adjuvants, with oncology, infectious disease, and other mRNA programs.
Mainland ChinaFull profile →
Founded in 2019, the company discloses mRNA molecular engineering, delivery, and immunomodulation platforms with CMC integrated into technology development.
Mainland ChinaFull profile →
IN006 is a bivalent RSV vaccine based on the company's mRNA and LNP platforms. The company reported completion of Phase 2 enrollment and vaccination in 2025; IN026 received FDA IND clearance in 2026.
Mainland ChinaFull profile →
A clinical-stage self-replicating RNA technology developer spanning infectious diseases, immunology, and other therapeutic areas.
United StatesFull profile →
Founded in 2019, the company develops self-amplifying RNA vaccines and therapeutics and LNP platforms.
BelgiumFull profile →
Explicitly offers small-molecule MicroED and presents protein and peptide MicroED examples, separately from SPA services.
Mainland China / United StatesFull profile →
Offers lipid- and polymer-based nonviral delivery systems, LNP/PNP formulation optimization, and manufacturing for mRNA and other nucleic acid payloads.
SpainFull profile →
GenScript's life science business offers IVT RNA and LNP-related services. Its ProBio subsidiary provides CGT CMC services including mRNA vaccines and nucleic acid drugs. Entity information uses GenScript group-level data.
United States / Mainland ChinaFull profile →
In 2023 Daiichi Sankyo announced Japanese approval of its DAICHIRONA (DS-5670) mRNA COVID-19 vaccine. The approved product should be evaluated separately from other newer programs.
JapanFull profile →
The company's first mRNA Japanese encephalitis vaccine, GBP560, entered Phase 1/2 trials in Australia and New Zealand. It is distinct from its existing non-mRNA vaccines.
South KoreaFull profile →
A historical partner page describes Stemirna's mRNA vaccine and nanolipid/polymer delivery R&D. The company's website was inaccessible during this review; current operations and clinical status remain unverified.
Mainland ChinaFull profile →
Alaya is a preclinical in vivo CAR-T developer. Its disclosed polymeric nanoparticle platform encapsulates lentiviral CAR vectors for targeted T-cell transduction; this is a hybrid polymer/viral approach, not simply a nonviral polymer delivery system.
The annual report confirms CRO services through a virus-assessment platform, including clinical strain testing and antiviral drug/vaccine evaluation for pharmaceutical clients. Drugs and APIs remain the group’s core business; included as diversified.
Mainland ChinaFull profile →
Beam develops investigational precision genetic medicines using base editing. Its website describes a delivery strategy spanning electroporation and nonviral and viral approaches. Those routes include different applications; the platform label alone does not establish in vivo efficacy.
United StatesFull profile →
VivoVec uses engineered lentiviral vectors for in vivo CAR-T. The disclosed pipeline includes CD22 UB-VV400/410 and BCMA×GPRC5D UB-VV500. IASO retains Greater China rights to the partnered CD22 programs; UB-VV111 is partnered with AbbVie. Trial registration and IND clearance do not establish efficacy.
United StatesFull profile →
AstraZeneca completed its acquisition in May 2025. ENaBL is a targeted lentiviral platform; anti-BCMA ESO-T01 has a published Phase 1 study in multiple myeloma. The small, uncontrolled study provides preliminary evidence, not established benefit.
BelgiumFull profile →
KLN-1010 is a BCMA-directed in vivo CAR-T candidate in Phase 1 for multiple myeloma, using the lentiviral iGPS platform. Lilly confirmed completion of the Kelonia acquisition in its Q2 2026 results. Early clinical findings remain investigational.
United StatesFull profile →
Interius develops targeted lentiviral in vivo CAR therapies. Its clinical lead INT2104 targets CD20 and engineers T and NK cells. Gilead’s annual filing confirms that the acquisition closed in October 2025; Interius is a wholly owned subsidiary.
United StatesFull profile →
NanoCell’s NanoCAR approach uses targeted LNPs to generate CAR-T cells in vivo. Its animal proof-of-concept disclosure describes nonviral DNA delivery; this should not be classified as a transient mRNA-only platform. Clinical efficacy remains unestablished.
United StatesFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.